Develop a 3D neurological disease model of human cortical glutamatergic neurons using micropillar-based scaffolds
Type
ArticleAuthors
Chen, ChengDong, Xin
Fang, Kai-Heng
Yuan, Fang
Hu, Yao
Xu, Min
Huang, Yu
Zhang, Xixiang

Fang, Danjun
Liu, Yan
KAUST Department
Material Science and Engineering ProgramPhysical Science and Engineering (PSE) Division
Date
2019-03-23Online Publication Date
2019-03-23Print Publication Date
2019-05Permanent link to this record
http://hdl.handle.net/10754/652839
Metadata
Show full item recordAbstract
Establishing an effective three-dimensional (3D) in vitro culture system to better model human neurological diseases is desirable, since the human brain is a 3D structure. Here, we demonstrated the development of a polydimethylsiloxane (PDMS) pillar-based 3D scaffold that mimicked the 3D microenvironment of the brain. We utilized this scaffold for the growth of human cortical glutamatergic neurons that were differentiated from human pluripotent stem cells. In comparison with the 2D culture, we demonstrated that the developed 3D culture promoted the maturation of human cortical glutamatergic neurons by showing significantly more MAP2 and less Ki67 expression. Based on this 3D culture system, we further developed an in vitro disease-like model of traumatic brain injury (TBI), which showed a robust increase of glutamate-release from the neurons, in response to mechanical impacts, recapitulating the critical pathology of TBI. The increased glutamate-release from our 3D culture model was attenuated by the treatment of neural protective drugs, memantine or nimodipine. The established 3D in vitro human neural culture system and TBI-like model may be used to facilitate mechanistic studies and drug screening for neurotrauma or other neurological diseases.Citation
Chen C, Dong X, Fang K-H, Yuan F, Hu Y, et al. (2019) Develop a 3D neurological disease model of human cortical glutamatergic neurons using micropillar-based scaffolds. Acta Pharmaceutica Sinica B. Available: http://dx.doi.org/10.1016/j.apsb.2019.03.004.Sponsors
This study was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDA16010306), the National Natural Science Foundation of China Grants (91849117 and 81471301), Key Research and Development Program of China (2016YFC1306703), The National Jiangsu Outstanding Young Investigator Program (BK20160044, China), Jiangsu Province׳s Innovation Person (China), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China Project (Grant No. 17KJB180010).Publisher
Elsevier BVJournal
Acta Pharmaceutica Sinica BAdditional Links
https://www.sciencedirect.com/science/article/pii/S2211383518313686ae974a485f413a2113503eed53cd6c53
10.1016/j.apsb.2019.03.004
Scopus Count
Except where otherwise noted, this item's license is described as This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).